A Swiss pharmaceutical company that develops and sells medicines for conditions like heart failure, immune disorders, and cancer, including the brands Entresto, Cosentyx, and Kisqali. It was created in 1996 when the Basel giants Ciba-Geigy and Sandoz merged — at the time the largest corporate merger in history — with roots reaching back over two and a half centuries. Its name comes from the Latin phrase "novae artes," meaning "new skills."
Pipeline progress: EC and Japan approved Rhapsido for CSU; EC approved Itvisma for broad SMA; FDA granted Kisqali pediatric exclusivity; BLA submitted for del-zota in DMD.
Full-year 2026 guidance reaffirmed: net sales expected to grow low single-digit, core operating income expected to decline low single-digit.
In July, Novartis agreed to acquire Myricx Bio, an ADC company, expected to close in H2 2026.
Novartis AG files Form 6-K for $10 billion multi-tranche notes offering
Novartis Capital Corporation issued $500M Floating Rate Notes due 2029, $1.25B 4.100% Notes due 2029, $1.75B 4.400% Notes due 2031, $2.0B 4.600% Notes due 2033, $2.25B 4.900% Notes due 2036, $1.0B 5.600% Notes due 2046, and $2.25B 5.700% Notes due 2056.
Show detailsHide details
The notes are guaranteed by Novartis AG and were sold under a Terms Agreement dated March 16, 2026 with underwriters including BNP Paribas, Citigroup, Deutsche Bank, J.P. Morgan, and Mizuho.
The filing is made to incorporate documents into the existing Form F-3 registration statement (File Nos. 333-282133 and 333-282133-01).
Exhibits include forms of guaranteed debt securities, officer's certificate, and legal opinions from Davis Polk & Wardwell LLP and Advestra AG.
Novartis reports 8% sales growth in 2025, proposes 5.7% dividend increase to CHF 3.70
Novartis delivered 8% sales growth and 14% core operating income growth in constant currencies in 2025, generating USD 17.6 billion in free cash flow.
Show detailsHide details
The company proposes a dividend increase of 5.7% to CHF 3.70 per share at the upcoming Annual General Meeting.
Novartis expects more than 30 potential high-value medicines and 15 submission-enabling readouts over the next two years.
Recent approvals include Rhapsido, Vanrafia, and Itvisma, with label expansions for Pluvicto and Scemblix.
The company plans a USD 23 billion investment in the US over five years to strengthen manufacturing, and proposes Charles Swanton for Board nomination.
Novartis reaffirms long-term sales growth outlook of 5-6% (cc) per year through the end of the decade.
FDA approves Novartis' Itvisma, first gene replacement therapy for SMA in patients aged 2 and older.
The FDA approved Itvisma (onasemnogene abeparvovec-brve) for children two years and older, teens, and adults with spinal muscular atrophy (SMA) and a confirmed SMN1 gene mutation.
Show detailsHide details
Itvisma is the first and only gene replacement therapy approved for this broad SMA population, delivered as a one-time fixed intrathecal dose that does not require adjustment for age or body weight.
Approval is based on data from the Phase III STEER study and supported by the Phase IIIb STRENGTH study, showing statistically significant improvements in motor function and stabilization over 52 weeks.
The most common adverse events in the STEER study were upper respiratory tract infection and pyrexia; in the STRENGTH study, common cold, pyrexia, and vomiting.
Itvisma will be available in the US in December, with Novartis Patient Support available at 1-855-441-4363 for insurance and financial assistance.
Novartis holds exclusive worldwide licenses from Nationwide Children's Hospital, REGENXBIO, and Généthon for AAV9 gene replacement therapy for SMA.
Novartis rolls forward mid-term guidance to +5-6% cc sales CAGR for 2025-2030
Peak sales guidance raised for Kisqali to USD 10 billion+ and Scemblix to USD 4 billion+.
Show detailsHide details
Novartis projects a +5-6% constant currency sales CAGR for 2025-2030, following an upgrade of its 2024-2029 guidance to +6% cc.
Company now has eight de-risked, in-market assets with USD 3-10 billion peak sales potential.
Expects 15+ potentially submission-enabling readouts in the next two years and a pipeline of 30+ potential high-value medicines.
Core operating income margin was 41.2% in first nine months of 2025; expects to return to 40%+ margins by 2029 after absorbing dilution from Avidity acquisition.